Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan;98(1):6-16.
doi: 10.1111/php.13435. Epub 2021 May 16.

Ruthenium-based Photoactive Metalloantibiotics

Affiliations
Review

Ruthenium-based Photoactive Metalloantibiotics

Avijita Jain et al. Photochem Photobiol. 2022 Jan.

Abstract

Antibiotic resistance is one of the world's most urgent public health problems. Antimicrobial photodynamic therapy (aPDT) is a promising therapy to combat the growing threat of antibiotic resistance. The aPDT combines a photosensitizer and light to generate reactive oxygen species to induce bacterial inactivation. Ruthenium polypyridyl complexes are significant because they possess unique photophysical properties that allow them to produce reactive oxygen species upon photoirradiation, which leads to cytotoxicity. These antimicrobial agents cause bacterial cell death by DNA and cytoplasmic membrane damage. This article presents a comprehensive review of photoactive antimicrobial properties of kinetically inert and labile ruthenium complexes, nanoparticles coupled photoactive ruthenium complexes, and photoactive ruthenium nanoparticles. Additionally, limitations of current ruthenium-based photoactive antimicrobial agents and future directions for the development of antibiotic-resistant photoactive antimicrobial agents are discussed. It is important to raise awareness for the ruthenium-based aPDT agents in order to develop a new class of photoactive metalloantibiotics capable of combating antibiotic resistance.

PubMed Disclaimer

Similar articles

Cited by

References

REFERENCES

    1. Centers for Disease Control and Prevention (2021). Available at: https://www.cdc.gov/drugresistance/biggest-threats.html. Accessed on 20 March 2021.
    1. Frei, A., J. Zuegg, A. G. Elliott, M. Baker, S. Braese, C. Brown, F. Chen, C. G. Dowson, G. Dujardin, N. Jung, A. P. King, A. M. Mansour, M. Massi, J. Moat, H. A. Mohamed, A. K. Renfrew, P. J. Rutledge, P. J. Sadler, M. H. Todd, C. E. Willans, J. J. Wilson, M. A. Cooper and M. A. T. Blaskovich (2020) Metal complexes as a promising source for new antibiotics. Chemical Science 11, 2627-2639.
    1. Kean, W. F. and I. R. Kean (2008) Clinical pharmacology of gold. Inflammopharmacology 16, 112-125.
    1. Jamieson, E. R. and S. J. Lippard (1999) Structure, recognition, and processing of cisplatin−DNA adducts. Chem. Rev. 99, 2467-2498.
    1. Reedijk, J. (1999) Why does cisplatin reach guanine-n7 with competing s-donor ligands available in the cell? Chem. Rev. 99, 2499-2510.

Publication types

MeSH terms

LinkOut - more resources